Blueprint Medicines (BPMC) PT Raised to $130 at Needham
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/28/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailGet Alerts BPMC Hot Sheet
Price: $129.46 --0%
Rating Summary:
11 Buy, 18 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 18
Rating Summary:
11 Buy, 18 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 18
Join SI Premium – FREE
Needham analyst Ami Fadia raised the price target on Blueprint Medicines (NASDAQ: BPMC) to $130.00 (from $97.00) while maintaining a Buy rating.
You May Also Be Interested In
- Canaccord Downgrades Botanix Pharmaceuticals Ltd (BOT:AU) to Hold
- Zymeworks (ZYME) PT Raised to $35 at Truist Securities
- JPMorgan Upgrades Hiwin Technologies (2049:TT) to Neutral
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
